{"prompt": "['2014-0546', 'August 7, 2017', 'Page 43 of 49', 'Revised IWG-MRT and ELN Response Criteria for Myelofibrosis', '(4)', 'See above for definitions of anemia response, spleen response, and progressive disease. Increase in severity of anemia', 'constitutes the occurrence of new transfusion dependency or a > 20 g/L decrease in hemoglobin level from', 'pretreatment baseline that lasts for at least 12 weeks. Increase in severity of thrombocytopenia or neutropenia is', 'defined as a 2-grade decline, from pretreatment baseline, in platelet count or absolute neutrophil count, according to', 'the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. In addition, assignment to CI requires a', 'minimum platelet count of > 25,000 x 109/L and absolute neutrophil count of > 0.5 x 109/L.', '(5)', 'Applicable only to patients with baseline hemoglobin of < 100 g/L. In patients not meeting the strict criteria for', 'transfusion dependency at the time of study enrollment (see as follows), but have received transfusions within the', 'previous month, the pretransfusion hemoglobin level should be used as the baseline.', '(6) Transfusion dependency before study enrollment is defined as transfusions of at least 6 units of packed red blood cells', '(PRBC), in the 12 weeks prior to study enrollment, for a hemoglobin level of < 85 g/L, in the absence of bleeding or', 'treatment-induced anemia. In addition, the most recent transfusion episode must have occurred in the 28 days prior to', 'study enrollment. Response in transfusion-dependent patients requires absence of any PRBC transfusions during any', 'consecutive \"rolling\" 12-week interval during the treatment phase, capped by a hemoglobin level of > 85 g/L.', '(7)', 'In splenectomized patients, palpable hepatomegaly is substituted with the same measurement strategy.', '(8)', 'Spleen or liver responses must be confirmed by imaging studies where a > 35% reduction in spleen volume, as', 'assessed by MRI or CT, is required. Furthermore, a > 35% volume reduction in the spleen or liver, by MRI or CT,', 'constitutes a response regardless of what is reported with physical examination.', '(9)', 'Symptoms are evaluated by the MPN-SAF TSS (Emanuel 2012). The MPN-SAF TSS is assessed by the patients', 'themselves and this includes fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain,', 'abdominal discomfort, weight loss, and fevers. Scoring is from 0 (absent/as good as it can be) to 10 (worst', 'imaginable/as bad as it can be) for each item. The MPN-SAF TSS is the summation of all the individual scores (0-100', 'scale). Symptoms response requires > 50% reduction in the MPN-SAF TSS.', '(10) Progressive disease assignment for splenomegaly requires confirmation by MRI or CT showing a > 25% increase in', 'spleen volume from baseline. Baseline values for both physical examination and imaging studies refer to pretreatment', 'baseline and not to post-treatment measurements.']['2014-0546', 'August 7, 2017', 'Page 44 of 49', 'Appendix 5: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-', 'SAF TSS)', 'MRN', 'Name', '1 to 10 (0 if absent) ranking', 'Symptom', '1 is most favorable and 10 least favorable', 'Please rate your fatigue (weariness,', 'tiredness) by circling the one number', '(No fatigue) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)', 'that best describes your WORST level', 'of fatigue during the past 24 hours', 'Circle the one number that describes how, during the past week, much', 'difficulty you have had with each of the following symptoms', 'Numbess/Tingling in hands and feet', '(Absent) 0 1 2 3 4 5 6 7 8 9 10', '(Worst Imaginable)', 'Night Sweats', '(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)', 'Itching (pruritus)', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', 'Bone Pain', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', '(Diffuse - not joint pain or arthritis)', 'Fever (>100F)', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', 'Unintentional weight loss last 6', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', 'months', 'Filling up quickly when you eat', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', '(Early satiety)', 'Abdominal Discomfort', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', 'Inactivity', '(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)', 'Problems with concentration -', '(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)', 'compared to prior to my MPD']\n\n###\n\n", "completion": "END"}